📈 Investment Details: The Serum Institute of India, the world’s largest vaccine maker, has acquired a 3.9% stake in London-listed Oxford Biomedica (OXB.L) for £50 million ($68 million). This investment will fund the expansion of Oxford Biomedica's 84,000 sq. ft manufacturing facility, Oxbox, in Oxford.

💹 Share Purchase: The Serum Institute will buy 3.4 million newly issued shares at 1,478 pence each, reflecting Oxford Biomedica's closing price on Tuesday.

👥 Job Creation: The partnership is expected to create up to 120 new jobs.

📊 Company Growth: Oxford Biomedica, known for its role in COVID-19 vaccine production for AstraZeneca, reported a revenue increase to £81.3 million in the first half of the year, doubling from £34 million in the same period last year. It swung to a pre-tax profit of £19.2 million from a previous loss of £6.1 million.

📈 Stock Reaction: Oxford Biomedica’s shares rose 6% following the announcement.

🌐 Future Outlook: The company anticipates new partnerships and additional revenue streams, though it will also face reduced revenue due to planned cleanings and recalibration of its manufacturing suites.